Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2025

Genmab — November 2025

Planlagt Fastgjort Låst Flyttet Genmab
176 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #93

    Jyske sætte Gmab på HOLD PT2000. Efter et pænt kursrun anses Genmab-aktien nu for at være mere fair værdiansat.

    1 Reply Last reply
    0
    • L Offline
      L Offline
      lahn1
      wrote on sidst redigeret af
      #94

      Samtidig forventes nyhedsflowet for resten af 2025 og begyndelsen af 2026 at blive mere afdæmpet, hvor resten af 2025 byder på: 1) Potentiel godkendelse af Epkinly i FL, hvor FDA har sat godkendelsesdatoen til 30. november 2025. Genmab ser ingen årsager til, at produktet ikke skulle blive godkendt.

      1 Reply Last reply
      0
      • L Offline
        L Offline
        lahn1
        wrote on sidst redigeret af
        #95
        1. Opfølgende fase 2-data på acasunilimab i NSCLC, som bliver præsenteret på ESMO den 10.–12. december. Ser vi frem mod 2026, begynder året roligt, mens andet halvår byder på fase 3-data for Epkinly + R-CHOP i 1L DLBCL (EPCORE DLBCL-2) og data i 2L DLBCL (EPCORE DLBCL-1) samt fase 3-data for RINA-S i RAINFALL-02-studiet.
        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #96

          i am a bit troubled by the fact that they still show a P/E of 124 in their analysis, they still have mistakes in their spreadsheet, probably mixing $ and DKK... via the pdf here
          https://www.jyskebank.dk/finansnyt/aktier/publikation/oktober-2025

          1 Reply Last reply
          0
          • L Offline
            L Offline
            lahn1
            wrote on sidst redigeret af
            #97

            Ja EL det er foruroligende for passer nogle af deres tal så 🙂

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #98

              https://clinicaltrials.gov/study/NCT07226752 new trial in China, while Chinese centers in EPCORE DLBCL-1 are removed, looks like they want to separate the Chinese part
              https://clinicaltrials.gov/study/NCT04628494?tab=history&a=49&b=50&compareMode=sideBySide#version-content-panel

              1 Reply Last reply
              0
              • R Offline
                R Offline
                Raun
                wrote on sidst redigeret af
                #99

                Op ned op ned op ned....... 4.5% oppe i US til aften 🙂 ... Ca. svarende til 1950dkr.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #100

                  https://pj.jiho.jp/article/254090 anssen Pharmaceutical (J&J) said on October 31 that it has filed the combination of its bispecific antibodies Talvey (talquetamab) and Tecvayli (teclistamab) in rMM - i don't think they have filed this with the FDA already?

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #101

                    Reduced Risk of Cardiovascular Disease Observed With Teprotumumab vs Corticosteroids https://www.aao.org/education/editors-choice/reduced-risk-of-cardiovascular-disease-observed-wi

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #102

                      BioNTech Innovation Series R&D Day 2025 https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2025/11/11/13-27-51/BNTX Innovation Series (R%26D) Day 2025_final_ website.pdf mostly for BNT314 /GEN1059 , GEN1042 still in the pipeline

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #103

                        175 slides 🙂

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gentogen
                          wrote on sidst redigeret af
                          #104

                          Nr. 42 og 133 ....

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #105

                            Merus will hold it's Extraordinary General Meeting December 9, 2025

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              lahn1
                              wrote on sidst redigeret af
                              #106

                              what the chance they vote down the takeover ? 😄

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #107

                                Genmab pushes rina-S into its third phase 3
                                13 November 2025 https://www.oncologypipeline.com/apexonco/genmab-pushes-rina-s-its-third-phase-3

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #108

                                  Epcoritamab for Relapsed/Refractory EBV+ Post-Transplant Lymphoproliferative Disorder of DLBCL-Type https://onlinelibrary.wiley.com/doi/10.1002/jha2.70156

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #109

                                    Thanks. Fantastic case.

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      lahn1
                                      wrote on sidst redigeret af
                                      #110

                                      Nice story EL

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #111

                                        Genmab/Kepler: Dækning genoptages med neutral anbefaling og kursmål på 2100 kr.

                                        1 Reply Last reply
                                        0
                                        • B Offline
                                          B Offline
                                          bibob
                                          wrote on sidst redigeret af
                                          #112

                                          Tak @jky. Så er der plads til mere og en købsanbefaling. D 😄

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper